detail content area
PLoS ONE, 2020.15(5), e0232757-0, DOI: https://doi.org/https:// doi.org/10.1371/journal.pone.0232757
Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus
Jang-Hoon Choi, Hye-Min Woo;Tae-young Lee;So-young Lee;Sang-Mu Shim;Woo- Jung Park;Jeong-Sun Yang;Joo Ae Kim;Mi-Ran Yun;Dae-Won Kim;Sung Soon Kim;Yi Zhang, Wei Shi;Lingshu Wang;Barney S. Graham;John R. Mascola;Nanshuang Wang;Jason S. McLellan;Joo-Yeon Lee;Hansaem Lee
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection and continues to infect humans, thereby contributing to a high mortality rate (34.3% in 2019). In the absence of an available licensed vaccine and antiviral agent, therapeutic human antibodies have been suggested as candidates for treatment. In this study, human monoclonal antibodies were isolated by sorting B cells from patient’s PBMC cells with prefusion stabilized spike (S) probes and a direct immunoglobulin cloning strategy. We identified six receptor-binding domain (RBD)-specific and five S1 (non-RBD)-specific antibodies, among which, only the RBD-specific antibodies showed high neutralizing potency (IC50 0.006–1.787 μg/ml) as well as high affinity to RBD. Notably, passive immunization using a highly potent antibody (KNIH90-F1) at a relatively low dose (2 mg/kg) completely protected transgenic mice expressing human DPP4 against MERS-CoV lethal challenge. These results suggested that human monoclonal antibodies isolated by using the rationally designed prefusion MERS-CoV S probe could be considered potential candidates for the development of therapeutic and/or prophylactic antiviral agents for MERS-CoV human infection.
- DOI: https://doi.org/https:// doi.org/10.1371/journal.pone.0232757
- ISBN or ISSN: 1932-6203
- 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
- This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.